• linkedin
  • Increase Font
  • Sharebar

    Topical Cyclosporine Beneficial in Dry Eye Syndrome

    Emulsion treatment leads to improved quality of life and favorable cost-effectiveness ratios

    TUESDAY, Feb. 10 (HealthDay News) -- In patients with moderate to severe dry eye syndrome who don't respond to conventional lubricant therapy, treatment with topical cyclosporine emulsion improves quality of life and is cost-effective, researchers report in the February issue of the Archives of Ophthalmology.

    Melissa M. Brown, M.D., of the University of Pennsylvania School of Medicine in Philadelphia, and colleagues analyzed data from two multicenter, randomized, clinical trials and U.S. Food and Drug Administration files for topical cyclosporine.

    The researchers found that topical cyclosporine (0.05 percent) is associated with an average 4.3 percent improvement in patient quality of life. They also found that the third-party-insurer incremental and perspective average cost-utility ratios per quality-adjusted life-year are $37,179 and $34,343, respectively.

    "These value gains are considerably more than the 1 percent to 2 percent gain conferred by alpha-adrenergic blockers for the treatment of prostate hyperplasia and also compare favorably with the 4 percent gain conferred by the commonly prescribed hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) for the treatment of hyperlipidemias," the authors write. "The use of topical cyclosporine for the treatment of moderate to severe dry eye syndrome is cost-effective because it is well under the conventional U.S. standard of $50,000 per quality-adjusted life-year that most would likely agree is cost-effective."

    This study was supported by Allergan, Inc., the Center for Value-Based Medicine, and the Eye Research Institute. Authors of the study report a relationship with the company.

    Abstract
    Full Text

    Copyright © 2009 ScoutNews, LLC. All rights reserved.